Analytical Data
-
Gene name
TRBC1
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N- MBP & C- His-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01850
-
Expression Region
1-129aa
-
Molecular Weight
62.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRBC1, or T-cell receptor beta chain constant region 1, plays a vital role in the adaptive immune response by encoding a component of the T-cell receptor (TCR) complex, which is crucial for T-cell recognition of antigens. Research into TRBC1 is gaining momentum due to its potential implications in immunology and cancer therapy. Abnormalities in TCR expression, including TRBC1, have been linked to various diseases, particularly cancers like leukemias and lymphomas, where T-cell malignancies arise from genetic alterations. Understanding the structure and function of TRBC1 can pave the way for novel therapeutic approaches, including TCR-engineered T cell therapies aimed at enhancing the immune system's ability to target and destroy cancer cells. Additionally, investigating TRBC1's role in immune disorders may lead to better diagnostic markers and treatment strategies. Recombinant TRBC1 proteins are increasingly used in research to elucidate its interactions and functionality within the TCR complex, contributing to a more comprehensive understanding of T-cell biology and the development of targeted immunotherapies. Such studies could ultimately lead to significant advancements in treating immune-related diseases.
